医学信息
醫學信息
의학신식
MEDICAL INFORMATION
2014年
8期
363-363
,共1页
食管癌%紫杉醇%临床观察
食管癌%紫杉醇%臨床觀察
식관암%자삼순%림상관찰
Esophageal carcinoma%Paclitaxel%Clinical observation
目的：探讨紫杉醇联合顺铂治疗晚期食管癌的临床疗效及不良反应。方法紫杉醇135 mg/m2,静脉滴入, d1；顺铂25 mg/m2,静脉滴入, d1~d3,21 d为1个周期。结果实验组和对照组有效率分别为53.33%和37.03％．不良反应方面：程度较轻，未影响化疗。结论紫杉醇联合顺铂是治疗晚期食管癌的是有效方案，不良反应下降，患者的耐受性好。
目的：探討紫杉醇聯閤順鉑治療晚期食管癌的臨床療效及不良反應。方法紫杉醇135 mg/m2,靜脈滴入, d1；順鉑25 mg/m2,靜脈滴入, d1~d3,21 d為1箇週期。結果實驗組和對照組有效率分彆為53.33%和37.03％．不良反應方麵：程度較輕，未影響化療。結論紫杉醇聯閤順鉑是治療晚期食管癌的是有效方案，不良反應下降，患者的耐受性好。
목적：탐토자삼순연합순박치료만기식관암적림상료효급불량반응。방법자삼순135 mg/m2,정맥적입, d1；순박25 mg/m2,정맥적입, d1~d3,21 d위1개주기。결과실험조화대조조유효솔분별위53.33%화37.03％．불량반응방면：정도교경，미영향화료。결론자삼순연합순박시치료만기식관암적시유효방안，불량반응하강，환자적내수성호。
Objective: To study the curative ef ect and side ef ect of paclitaxel combined with cisplatin in the treatment of advanced esophageal cancer. Methods:Paclitaxel 135 mg/m2, intravenous drip, D1;cisplatin 25 mg/m2, intravenous drip, D1~D3, 21 d for 1 cycles. Results:the group ef iciency is respectively 53.33%and 37.03%. adverse ef ects of the experimental group and the control: to a lesser extent, did not af ect the chemotherapy. Conclusion: the combination of paclitaxel and cisplatin treatment of advanced esophageal carcinoma is ef ective, adverse reaction decreased and good patient tolerance.
